Private Equity

Selected Investments: Healthcare

Activate Healthcare was formed with the goal of transforming healthcare by delivering primary care through workplace health clinics that engage the patient, support a culture of health, guide the healthcare continuum to lower costs and enable employers of all sizes to benefit from dedicated care. The Company currently serves approximately 40 to 50 employers through 20 clinics. Activate's primary care and acute care clinics improve short-term healthcare costs, including lowering emergency room visits and increasing generic drug usage, and long-term healthcare costs, typically by managing chronic issues such as obesity, high blood pressure and diabetes.
www.activatehealthcare.com

AGI Dermatics is a bio-pharmaceutical company that develops and sells high-end skincare products and cosmetic ingredients. The Company's core products are based on DNA repair enzymes that are intended to complement skin cells' natural DNA repair capacity. AGI Dermatics was acquired by the Estee Lauder Companies (NYSE: EL) in September 2008.


Alphatec (NASDAQ: ATEC), parent company to Alphatec Spine, is a medical technology company focused on the development of products for the surgical treatment of spine disorders. The Company's primary focus is on the aging spine, which leverages its broad product portfolio and pipeline to address one of the highest growth sectors in the orthopedics industry.
www.alphatecspine.com
Aton Pharma was formed to acquire under-managed specialty drug assets from large pharmaceutical companies. Aton's strategy was to acquire portfolios of "orphan" drugs at an attractive valuation and, through improved distribution, customer education and product enhancement, provide unique medicines to patients worldwide. Aton Pharma was acquired by Valeant Pharmaceuticals International, Inc. (NYSE: VRX) in May 2010.
Doctor.com is the leading provider of cloud-based marketing automation solutions built specifically for healthcare industry. More than 20,000 providers rely on the company’s services to acquire new patients, develop and protect their online reputation, and maintain a strong digital presence everywhere patients search.
www.doctor.com
GlucoVista has patented technology to perform safe and accurate noninvasive testing of blood glucose levels. The Company is developing a handheld device that takes glucose measurements via infrared radiation emitted from the temporal area of the forehead. Initial clinical studies indicate that GlucoVista's prototype device is accurate within FDA guidelines.
www.glucovista.com
Hurel uses cell biology and microfluidics to help drug companies predict pre-clinically the drug candidates with the best chances of winning FDA approval. The Company's product tests the toxicity and metabolic effects of new drug candidates using proprietary cell assays with significantly longer lives than those currently on the market. The Company is also developing a flow product that will allow drug researchers to mimic the interaction of organs during the drug development process, effectively creating a "body on a chip."
www.hurelcorp.com
IsoPlexis has developed a single-cell multiplexing immunoassay and software suite that provides in-depth biological characterization of important immune and cancer cell subsets. The tool is able to identify and characterize up to 45 secreted proteins on a single-cell basis and enables the discovery of novel biomarkers and accurate testing of molecules in the development of immunotherapies.
www.isoplexis.com
MedAvante has developed a new method for patient assessment in Phase II and Phase III central nervous system clinical drug trials. Clinical trials for central nervous system drugs evaluate treatments for conditions such as mood, neurological disorders, or pain that cannot be measured objectively. The Company's testing method is designed to provide faster, more accurate, and more reliable results, which reduces the overall cost and time to market for new central nervous system drugs.
www.medavante.com
Oncoceutics is a clinical-stage biopharmaceutical company pursuing the discovery and development of highly differentiated treatments for difficult cancers. Its lead candidate, ONC201, is an oral, small-molecule drug that acts against numerous tumor types by sparing healthy cells and targeting the most potent tumor suppressor pathways. ONC201 is currently in four clinical trials – a Phase I/II trial in solid tumors at the Rutgers Cancer Institute of New Jersey, a Phase II glioblastoma trial at Massachusetts General Hospital, and two Phase I/II trials in Non-Hodgkin’s lymphoma and acute leukemias at MD Anderson Cancer Center.
www.oncoceutics.com
Preferred Pet Care operates veterinary hospitals in California. The Company enhances revenue and profitability by recruiting veterinarians who have established books of business and benefits from economies of scale, centralized management and the addition of ancillary products and services.
www.prefurredpetcare.com

The information provided herein should not be considered a recommendation to purchase or sell any particular investment. There is no assurance that any investment discussed herein will remain in the relevant fund at the time you review this website. The investments discussed do not represent the relevant fund's entire holdings. It should not be assumed that any of the investments discussed was or will prove to be profitable, or that the investment recommendations or decisions SMC makes in the future will be profitable or equal the performance of the investments discussed herein.